The relationship of haemoglobin level and survival: direct or indirect effects?

被引:29
作者
Levin, A [1 ]
机构
[1] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
关键词
anaemia; cardiovascular disease; chronic kidney disease; erythropoietin; haemoglobin; survival;
D O I
10.1093/ndt/17.suppl_5.8
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
The relationship between haemoglobin (Hb) level and survival in patients with chronic kidney disease (CKD) is complex. This paper explores the physiological basis for the hypothesis that Hb level and survival are causally related in this patient group, and assesses the current state of knowledge from clinical studies. Issues related to the methodology and analysis of clinical studies limit the certainty with which conclusions regarding the direct relationship between Hb level and survival can be drawn. The data support the concepts that Hb level is associated with survival in patients both with and without CKD, that changes in Hb level are associated with cardiovascular disease (CVD), and that CVD is prevalent in patients with CKD. Hb level is affected by nutritional status, inflammation, and the availability and effectiveness of human recombinant erythropoietin (rHuEPO) therapy, as well as by the degree of kidney function. Thus, the complexity of the relationships between Hb level, CVD and survival in patients with CKD requires further study from both the mechanistic and the clinical perspective. Properly designed clinical trials with survival as an endpoint, as well as data from prospectively measured modifiers of Hb levels and other markers of CVD, are needed to determine the physiological and statistical interaction of these factors in clinical practice.
引用
收藏
页码:8 / 13
页数:6
相关论文
共 67 条
[1]   Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction [J].
Al-Ahmad, A ;
Rand, WM ;
Manjunath, G ;
Konstam, MA ;
Salem, DN ;
Levey, AS ;
Sarnak, MJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (04) :955-962
[2]  
[Anonymous], 1997, Am J Kidney Dis, V30, pS192
[3]  
ASTOR BC, 2002, ARCH INTERN MED
[4]   Risk of Alzheimer's disease among elderly patients with anemia: Population-based investigations in Olmsted County, Minnesota [J].
Beard, CM ;
Kokmen, E ;
OBrien, PC ;
Ania, BJ ;
Melton, LJ .
ANNALS OF EPIDEMIOLOGY, 1997, 7 (03) :219-224
[5]   Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction [J].
Beattie, JN ;
Soman, SS ;
Sandberg, KR ;
Yee, J ;
Borzak, S ;
Garg, M ;
McCullough, PA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (06) :1191-1200
[6]   Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders [J].
Benz, RL ;
Pressman, MR ;
Hovick, ET ;
Peterson, DD .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (06) :1052-1060
[7]   A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study) [J].
Benz, RL ;
Pressman, MR ;
Hovick, ET ;
Peterson, DD .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (06) :1089-1095
[8]   Defining a renal anemia management period [J].
Besarab, A ;
Levin, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (06) :S13-S23
[9]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[10]  
Brandberg Y, 2000, MED ONCOL, V17, pS23